Single Ascending Dose Study of Intraperitoneal Triferic (Ferric Pyrophosphate Citrate) in Patients on Chronic Peritoneal Dialysis

Trial Profile

Single Ascending Dose Study of Intraperitoneal Triferic (Ferric Pyrophosphate Citrate) in Patients on Chronic Peritoneal Dialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Ferric pyrophosphate (Primary) ; Ferric pyrophosphate
  • Indications Iron deficiency anaemia
  • Focus Pharmacokinetics
  • Sponsors Rockwell Medical Technologies
  • Most Recent Events

    • 05 Apr 2018 According to a Rockwell Medical media release, data from the study will be presented at the National Kidney Foundation (NKF) Spring Clinical Meetings (2018).
    • 28 Feb 2018 According to a Rockwell Medical India media release, data will be presented at the Annual Dialysis Conference 2018.
    • 30 Oct 2017 According to a Rockwell Medical India media release, data from the study will be presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top